|
Home>Homoeopathy>Homoeoprophylaxis
(HP)
Parents
are encouraged to make informed decisions, based on information gained from
a wide variety of sources, as to the best choice of disease prevention for
themselves and their dependants.
Three
good starting points for research are:-
http://www.avn.org.au
http://immunise.health.gov.au/handbook.htm
Vaccination? A Review of
Risks and Alternatives 6th Edition, 2005, by Isaac Golden
Homoeoprophylaxis (HP) is the use of
homoeopathically prepared substances to prevent targeted diseases in
recipients. It’s first use, in an epidemic of Scarlet Fever, was documented
in 1801. It has been used throughout the world since then for both short
term and long term preventative purposes. Since then there has been
significant clinical experience in the use of HP for disease prevention
however public health authorities do not except this evidence as proof of
efficacy.
The term “homoeopathic
vaccination” is a misnomer. Vaccination, a well-understood medical
term, relies on antibody formation. Homoeopathic medicines do not rely on
antibody formation. They affect the patient’s initial predisposition to an
illness, rather than the antibody/antigen reaction.
Two large studies were
conducted in Brazil :-
-
In 1974 during an
epidemic of meningitis, 18,640 children were treated
homoeoprophylactically and 6,340 were not. In the treated group four cases
of meningitis were reported, in the untreated group, 32 cases were
reported (Eizayaga, F.X. Treatise on Homeopathic Medicine.282-286,
E Marecel, Buenos Aires). Based on the attack rate in the unprotected
group, 94 cases would have been expected in the homoeopathically protected
group, had the remedies been ineffective.
-
On the basis of this, in
1998 in Blumenau, Brazil, a large-scale investigation of the use of
homoeoprophylaxis was undertaken in persons up to 20 years of age. In the
first six months of administration, the following results were obtained:
of the 65,826 protected homoeopathically, one case was reported and of the
23,532 not protected, 7 cases were reported. A 12-month follow-up reported
3 cases in the protected group and 13 cases in the unprotected group.
Statistical analysis demonstrated a 95% protection in children over six
months and 91% protection in children over 12 months. Mroninski, C.,
Adriano, E. & Mattos G. Meningococcin, its protective effect against
meningococcal disease, Homoeopathic LINKS 14 (4): 230-4, Winter,
2001).
Australian studies
on homoeoprophylaxis (HP) have been undertaken by Australian homoeopath and
statistician, Isaac Golden PhD, as part of his Doctoral studies through
Swinburne University, Victoria. His findings include the statistical
analysis of a fifteen year clinical study of HP. This study found the
overall effectiveness of the HP program was 90.4% The thesis also included a
favourable analysis of chronic health problems (or lack thereof) in children
covered by the HP program. The study may be viewed at:-
http://adt.lib.swin.edu.au/uploads/approved/adt-VSWT20050228.150047/public/02whole.pdf |
